Because ASA-deficient 17−/−A1 astrocytoma cells are not capable to degrade NBD sulfatide (Fig. 2C), they could be utilized to evaluate alternate sulfatide-hydrolyzing pathways using transgenic expression of ectopic deacylases. The gene discussed is ARSA; the disease is astrocytoma (excluding glioblastoma).